EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Intravenous kisspeptin 112–121 bolus does not acutely impact circulating vasopressin in humans

Francesca Galbiati iD, Franziska Plessow, Lacey Plummer, Mark B Campbell, Shwan Nazarloo, C Sue Carter, John M Davis, Karen K Miller, Rona S Carroll, Ursula B Kaiser, Stephanie B Seminara, Anna Aulinas und 1 weitere

Journal of Neuroendocrinology · 2026

DOI: 10.1111/jne.70114 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Neuroendocrinology, 2026. Verfasst von Francesca Galbiati und 12 weiteren Autor:innen. Beteiligte Einrichtung: Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Arginine Vasopressin, Kisspeptins, Vasopressins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NICHD NIH HHS, FDA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Arginine‐vasopressin (AVP) deficiency (AVP‐D) is caused by hypothalamic–pituitary damage of vasopressinergic neurons leading to polyuria and polydipsia. Diagnostic tests for AVP‐D are limited by low accuracy and/or tolerability. Kisspeptin (KP) stimulates AVP release in animals, but no study has investigated KP as a provocative test for AVP‐D in humans. We investigated circulating AVP levels in response to intravenous (IV) KP in adults. We also explored sex differences in AVP response to KP. Twelve healthy adults (50% female) received an IV KP bolus. Serum AVP was measured pre‐ and 10, 20, 40, and 60 min post‐KP. AVP levels were higher in males at all time points ( p = .028) and did not change in response to KP. KP did not stimulate AVP, possibly due to dose, administration route, or cross‐species differences in the AVP system. Our study does not support IV KP bolus of 0.24 nmol/kg as a provocative test for AVP‐D. Clinical Trial Registration Our study was registered on ClinicalTrials.gov (NCT00914823).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arginine VasopressinKisspeptinsVasopressinsAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, IntravenousInjections, Intravenous

Stichwörter der Autor:innen

arginine‐vasopressinkisspeptinprovocative testsex differences

Substanzen

Arginine VasopressinKISS1 protein, humanKisspeptinsVasopressins

Autor:innen und Institutionen

  • Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Faculty of Medicine, University of Vic-Central University of Catalonia (UVic-UCC), Vic/Manresa, Catalonia, Spain.
  • Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Psychiatry and Behavioral Sciences, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.
  • Reproductive Endocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Kinsey Institute, Indiana University, Bloomington, Indiana, USA.

ORCID-Profile: Francesca Galbiati, Elizabeth A Lawson

Förderung

  • NIMH NIH HHS
  • NICHD NIH HHS
  • FDA HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • NCRR NIH HHS
  • NIDDK NIH HHS
  • National Center for Translational Research in Reproduction and Infertility
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Galbiati, F., Plessow, F., Plummer, L., Campbell, M. B., Nazarloo, S., Carter, C. S., Davis, J. M., Miller, K. K., Carroll, R. S., Kaiser, U. B., Seminara, S. B., Aulinas, A., & Lawson, E. A. (2026). Intravenous kisspeptin 112–121 bolus does not acutely impact circulating vasopressin in humans. Journal of Neuroendocrinology. https://doi.org/10.1111/jne.70114

Vancouver

Galbiati F, Plessow F, Plummer L, Campbell MB, Nazarloo S, Carter CS, et al. Intravenous kisspeptin 112–121 bolus does not acutely impact circulating vasopressin in humans. Journal of Neuroendocrinology. 2026. doi:10.1111/jne.70114

BibTeX
@article{Galbiati2026,
  author = {Galbiati, Francesca and Plessow, Franziska and Plummer, Lacey and Campbell, Mark B and Nazarloo, Shwan and Carter, C Sue and Davis, John M and Miller, Karen K and Carroll, Rona S and Kaiser, Ursula B and Seminara, Stephanie B and Aulinas, Anna and Lawson, Elizabeth A},
  title = {Intravenous kisspeptin 112–121 bolus does not acutely impact circulating vasopressin in humans},
  journal = {Journal of Neuroendocrinology},
  year = {2026},
  doi = {10.1111/jne.70114}
}
Kostenlos starten →